ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Published Date: 24 Jun 2024

Phase II study found brigatinib exceeded historical control by shrinking 10% of targeted tumors

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

2.

The discovery of drug combinations may increase the life expectancy of children with brain cancer.

3.

Cancer Patients' Depression May Be Helped by Psilocybin.

4.

MRI Enhancement Predicts Breast Cancer in BRCA Carriers

5.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot